

DAFTAR PUSTAKA

- Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G.J., Marcocci, C., Perros, P., Salvi, M. and Wiersinga, W.M. 2016. The 2016 European thyroid association/European group on Graves Orbitopathy guidelines for the Management of Graves Orbitopathy. *European thyroid journal*, 5(1), pp.9-26.
- Bartalena, L., Macchia, P. E., Marcocci, C., Salvi, M., & Vermiglio, F. 2015. Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. *Journal of endocrinological investigation*, 38(4), 481-487.
- Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M.L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M.P., Lepri, A. and Rossi, G. 1998. Relation between therapy for hyperthyroidism and the course of Graves ophthalmopathy. *N Engl J Med*, 338(2), pp.73-78.
- Chang, E.L., Bernardino, C.R. and Rubin, P.A. 2004. Normalization of uhaler eyelid height and contour after bony decompression in thyroid-related ophthalmopathy: a digital image analysis. *AMA Arch Ophthalmol*, 122(12), pp.1882-1885.
- Chin, Y.H., Ng, C.H., Lee, M.H., Koh, J.W.H., Kiew, J., Yang, S.P., Sundar, G. and Khoo, C.M. 2020. "Prevalence of thyroid eye disease in Graves disease: A meta-analysis and systematic review". *Clin Endocrinol (Oxf)*. 2020;93:363–374.
- David, T.T. 2000. A simple maneuver to reposit a subluxed globe. *AMA Arch Ophthalmol*, 118(3), pp.410-411.
- Douglas, R.S., Kahaly, G.J., Patel, A., Sile, S., Thompson, E.H., Perdok, R., Fleming, J.C., Fowler, B.T., Marcocci, C., Marinò, M. and Antonelli, A. 2020. Teprotumumab for the treatment of active thyroid eye disease. *N Engl J Med*, 382(4), pp.341-352.
- Erb, M.H., Tran, N.H., McCulley, T.J. and Bose, S. 2003. Exophthalmometry measurements in Asians. *Invest Ophthalmol Vis Sci*, 44(13), pp.662-662.
- Federico, M. J., Covar, R. A., Brown, E. E., Leung, D. Y., & Spahn, J. D. (2005). Racial differences in T-lymphocyte response to glucocorticoids. *Chest*, 127(2), 571-578.
- Grecescu, M.L.C. 2021. Computed Tomography For Diagnosing Graves Ophthalmopathy. *Romanian medical Journal*, 68(2), p.269.
- Hart, R.H., Kendall-Taylor, P., Crombie, A. and Perros, P., 2005. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. *J Ocul Pharmacol Ther*, 21(4), pp.328-336.
- Hodgson, N.M. and Rajaii, F. 2020. Current understanding of the progression and management of thyroid associated orbitopathy: A systematic review. *Ophthalmology and therapy*, 9(1), pp.21-33.

- Huang, Y., Fang, S., Li, D., Zhou, H., Li, B. and Fan, X. 2019. The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy. *Eye*, 33(2), pp.176-182.
- Ito, K., Chung, K. F., & Adcock, I. M. 2006. Update on glucocorticoid action and resistance. *Journal of Allergy and Clinical Immunology*, 117(3), 522-543.
- Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K., & Pearce, S. H. 2018. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. *European thyroid journal*, 7(4), 167-186.
- Kahaly, G.J., Bartalena, L., Hegedüs, L., Leenhardt, L., Pohale, K. and Pearce, S.H. 2018. European thyroid association guideline for the management of Graves hyperthyroidism. *European thyroid journal*, 7(4), pp.167-186.
- Kahaly, G.J., Pitz, S., Hommel, G. and Dittmar, M. 2005. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves orbitopathy. *The Journal of Clinical Endocrinology & Metabolism*, 90(9), pp.5234-5240.
- Kahaly, G.J., Riedl, M., König, J., Pitz, S., Ponto, K., Diana, T., Kampmann, E., Kolbe, E., Eckstein, A., Moeller, L.C. and Führer, D. 2018. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. *Lancet Diabetes Endocrinol*, 6(4), pp.287-298.
- Kauhalinen-Mäkelin, R., Karma, A., Leinonen, E., Löyttyniemi, E., Salonen, O., Sane, T., Setälä, K., Viikari, J., Heufelder, A. and Välimäki, M. 2002. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. *Acta Ophthalmol Scand*, 80(3), pp.316-321.
- Kazim, M., Goldberg, R.A. dan Smith, T.J. 2002. "Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy". *AMA Arch Ophthalmol*, 120(3), pp.380-386.
- Liaboe, C.A., Clark, T.J., Shriver, E.M. and Carter, K.D. 2016. Thyroid Eye Disease: An Introductory Tutorial and Overview of Disease. *EyeRounds.org*.
- Macchia, P.E., Bagattini, M., Lupoli, G., Vitale, M., Vitale, G. and Fenzi, G. 2001. High-dose intravenous corticosteroid therapy for Graves ophthalmopathy. *J Endocrinol Invest*, 24(3), pp.152-158.
- Marcocci, C., Kahaly, G.J., Krassas, G.E., Bartalena, L., Prummel, M., Stahl, M., Altea, M.A., Nardi, M., Pitz, S., Boboridis, K. and Sivelli, P. 2011. Selenium and the course of mild Graves orbitopathy. *N Engl J Med*, 364(20), pp.1920-1931.
- Marcocci, C., Watt, T., Altea, M.A., Rasmussen, A.K., Feldt-Rasmussen, U., Orgiazzi, J. and Bartalena, L. 2012. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves orbitopathy: a questionnaire survey among members of the European Thyroid Association. *Eur J Endocrinol*, 166(2), pp.247-253.
- Morgenstern, K.E., Evanchan, J., Foster, J.A., Cahill, K.V., Burns, J.A., Holck, D.E.E., Perry, J.D. and Wulc, A.E. 2004. Botulinum toxin type a for

- dysthyroid uhaler eyelid retraction. *Ophthalm Plast Reconstr Surg*, 20(3), pp.181-185.
- Ponto, K.A., Pitz, S., Pfeiffer, N., Hommel, G., Weber, M.M. and Kahaly, G.J. 2009. "Quality of life and occupational disability in endocrine orbitopathy". *Deutsches Ärzteblatt International*, 106(17), pp.283.
- Rajendram, R., Bunce, C., Lee, R.W. and Morley, A.M. 2012. Orbital radiotherapy for adult thyroid eye disease. *Cochrane Database Syst Rev*, (7).
- Şahlı, E., & Gündüz, K. 2017. Thyroid-associated ophthalmopathy. *Turkish journal of ophthalmology*, 47(2), 94.
- Salvi, M. 2018. Step-down steroid-sparing therapy in active thyroid eye disease. *Nature Reviews Endocrinology*, 14(11), pp.634-635.
- Salvi, M., Vannucchi, G., Campi, I., Curro, N., Dazzi, D., Simonetta, S., Bonara, P., Rossi, S., Sina, C., Guastella, C. and Ratiglia, R., 2007. Treatment of Graves disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. *Eur J Endocrinol*, 156(1), pp.33-40.
- Saonanon, P. 2014. Update on Asian eyelid anatomy and clinical relevance. *Curr Opin Ophthalmol*, 25(5), pp.436-442.
- Smith, T. J. dan Hedegus, L., 2016. "Graves disease", *N Engl J Med*, 375(16), pp.1552-65.
- Smith, T.J., Koumas, L., Gagnon, A., Bell, A., Sempowski, G.D., Pihals, R.P. and Sorisky, A. 2002. "Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy". *Clin Endocrinol (Oxf)*, 87(1), pp.385-392.
- Stahn, C., & Buttgereit, F. 2008. Genomic and nongenomic effects of glucocorticoids. *Nature clinical practice Rheumatology*, 4(10), 525-533.
- Tantisira, K. G., Lasky-Su, J., Harada, M., Murphy, A., Litonjua, A. A., Himes, B. E., Weiss, S. T. 2011. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. *N Engl J Med*, 365(13), 1173-1183.
- Taylor, P., Rajendram, R., Uddin, J., Lee, R. and Dayan, C. 2017. Combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: A multi-centre, double-masked, factorial randomised controlled trial. *Society for Endocrinology BES 2017* (Vol. 50). BioScientifica.
- Thornton, J., Kelly, S.P., Harrison, R.A. and Edwards, R. 2007. Cigarette smoking and thyroid eye disease: a systematic review. *Eye*, 21(9), pp.1135-1145.
- Topilow, N.J., Tran, A.Q., Koo, E.B. and Alabiad, C.R.. 2020. Etiologies of Proptosis: A review. *Internal medicine review (Washington, DC: Online)*, 6(3).
- Tu, X., Dong, Y., Zhang, H. and Su, Q. 2018. Corticosteroids for Graves ophthalmopathy: systematic review and meta-analysis. *BioMed research international*.
- Walpole, S.C., Prieto-Merino, D., Edwards, P., Cleland, J., Stevens, G. and Roberts, I. 2012. The weight of nations: an estimation of adult human biomass. *BMC Public Health*, 12(1), pp.1-6.

- Wiersinga, W.M.. 2012. "Quality of life in Graves ophthalmopathy". *Baillieres Best Pract Res Clin Endocrinol Metab*, 26(3), pp.359-370.
- Wiersinga, W.M.. 2017. Advances in treatment of active, moderate-to-severe Graves ophthalmopathy. *Lancet Diabetes Endocrinol*, 5(2), pp.134-142.
- Ye, X., Bo, X., Hu, X., Cui, H., Lu, B., Shao, J. and Wang, J., 2017. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves orbitopathy. *Clinical endocrinology*, 86(2), pp.247-255.
- Zang, S., Ponto, K.A. and Kahaly, G.J. 2011. "Intravenous glucocorticoids for Graves orbitopathy: efficacy and morbidity". *Clin Endocrinol (Oxf)*, 96(2), pp.320-332.